Close Menu

NEW YORK (GenomeWeb News) – Biocept today set the price range on its planned initial public offering, saying it expects to price its shares between $10 and $12.

In its amended Form S-1 filed on Tuesday with the US Securities and Exchange Commission, the circulating tumor cell diagnostics firm said that it expects to offer about 1.8 million shares of its common stock, netting proceeds of approximately $17.1 million at the midpoint price of $11 per share. It would net $20.5 million if the underwriters exercise their overallotment option in full.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The founder of MeTooSTEM, BethAnn McLaughlin, created a Twitter account purported to be that of an LGBTQ Native American professor at Arizona State University, the New York Times writes.

Novavax reports its candidate SARS-CoV-2 vaccine leads to immune responses, according to the Sydney Morning Herald.

Gene length is associated with lifespan in a comparative genomics study appearing in the Proceedings of the National Academy of Sciences that draws on the whale shark genome.

In Nucleic Acids Research this week: effort to annotate the rat transcriptome, web-based resource to characterize marine microbes, and more.

Aug
18
Sponsored by
Bio-Rad

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Aug
19
Sponsored by
UgenTec

This webinar will present a case study from in vitro diagnostics developer SpeeDx on its experience building a complete sample-to-result workflow — encompassing instrumentation and data analysis software — for its qPCR-based ResistancePlus MG Mycoplasma genitalium assay.

Aug
25
Sponsored by
Roche

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

Sep
02
Sponsored by
ACD

This webinar will discuss the use of digital spatial profiling to test a gene therapy for CDKL5 deficiency disorder (CDD), a rare X-linked neurodevelopmental disease that causes severe seizures, global developmental delay, and limits a patient’s ability to communicate.